Inactive Instrument

Company EpiCept Corp Other OTC

Equities

US2942643048

Pharmaceuticals

End-of-day quote Other OTC
- USD 0.00% Intraday chart for EpiCept Corp

Business Summary

Immune Pharmaceuticals Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of novel targeted therapeutic agents in the fields of immunology, inflammation, dermatology and oncology. It operates though acquiring, developing and commercializing prescription drug products. Its lead product is bertilimumab, which is a fully human, anti-eotaxin-1, a regulator of immuno-inflammation. The Company is developing NanoCyclo, which is a nano-encapsulated formulation of cyclosporine-A for the treatment of atopic dermatitis and psoriasis. The Company's oncology portfolio includes Ceplene, which a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

Managers

Managers TitleAgeSince
Chief Executive Officer 37 21-04-11
Director of Finance/CFO 37 21-04-12
Chief Tech/Sci/R&D Officer - 17-12-10
Director/Board Member 56 17-08-14
Corporate Officer/Principal - -
Comptroller/Controller/Auditor 52 17-11-19

Members of the board

Members of the board TitleAgeSince
Director/Board Member 64 -
Director/Board Member 56 17-08-14
Director/Board Member 60 16-02-01
Director/Board Member 59 13-10-09
Director/Board Member 55 16-02-22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 3,713 0 0 100.00 %
Stock B 1 172,878,093 172,878,093 ( 100.00 %) 0

Company contact information

Immune Pharmaceuticals, Inc.

1 Bridge Plaza North Suite 270

07024, Englewood Cliffs

+201-464-2677

http://www.immunepharma.com
address EpiCept Corp